Panion presents at Animal Health Investment Europe, London, on 27 February 2019
Panion Animal Health AB develops an innovative treatment for epilepsy in dogs and has just started the clinical phase.
Panion has been selected to present its business plan at the 2019 Animal Health Investment Forum as part of the Innovation Showcase of the year, in the programme on translational technology from human-to-veterinary pharma.
Panion's chairman of the board, Lars Thunberg, will inform the audience about the promising business idea in veterinary medicines and the progress over the last two years. The focus will be on the commercial elements of Panion's business plan and sets out the possible road to commercialisation.
The Animal Health Investment Europe is a premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition and connecting those businesses with financial investors and strategic corporate partners.
The presentation slides can be seen here: https://bit.ly/2Iyn4p4
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.
Panion develops a gene therapy treatment for dogs with epilepsy. The clinical trial in dogs with real epilepsy will take place in the large investigator clinic, Long Island Veterinary Specialists (LIVS) in New York, USA. The study procedures are advancing well in accordance with the plan. The vector material is produced and undergoing testing procedures.
Panion is attracting interest from the agribusiness intelligence and animal health media Animal Pharm, where journalist Sian Lazell yesterday, 31.st of January 2019, noted the news on financing of the development program from Panion: https://bit.ly/2t1tgeK "Panion secures extra funding to back R&D. The financing round was carried out through the issuance of notes with warrants attached to Yorkville Advisors Global, that have a principal amount of SEK 100,000 each.
Panion Animal Health AB ("Panion") kallar på en andra tranche från den investeringsfond som förvaltas av Yorkville Advisors Global ("Yorkville").
Panion Animal Health AB ("Panion") draws down a second tranche from the investment fund managed by Yorkville Advisors Global ("Yorkville").
Panion Animal Health AB
Marknadsplats: Spotlight Stock Market
2019-04-25 Årsredovisning 2018